 As many people with
a DFU and PAD also have atherosclerotic disease in other
vascular beds, tight glucose control can be harmful. The
risk of hypoglycaemia is markedly lower when people are
only treated with metformin, a sodium glucose
cotransporter-2 inhibitor or a glucagon like peptide 1
receptor agonist. Tight glucose control is often not indicated in people with PAD and a DFU due to the risk of
hyp